Keyword: Valeant Pharmaceuticals
Intermountain's nonprofit drug making venture will be a "first-of-its-kind societal asset," according to Dan Liljenquist.
From Kaiser Health News: Following major price increases, use of the two cardiac medicines has dramatically decreased at 47 hospitals.
The year 2016 was a year of both stability and uncertainty in healthcare finance. FierceHealthFinance looks back at the most significant events of 2016 and what's ahead in 2017.
ARIAD Pharmaceuticals' decision to raise the price of its leukemia drug to nearly $200,000 a year has drawn the attention of some of the most prominent members of Congress.
The National Association for State Health Policy has floated proposals to combat rising drug prices.
Hospitals are bearing a large burden for skyrocketing drug costs, healthcare execs said at a recent press conference.
Presidential candidates Hillary Clinton and Donald Trump both have proposals that would likely curb the pricing practices of the pharmaceutical sector.
Hospitals say Valeant Pharmaceuticals has yet to provide promised discounts for its two heart drugs.